Dr Egan discusses the increased length of stay (LOS) resulting from improvement in mortality due to surfactant therapy in studies comparing surfactant vs placebo. Based on evidence, the introduction of surfactant therapy has led to significantly decreased mortality and morbidity without increasing resource utilization. The statements of Dr Egan regarding inverse correlation between mortality and LOS are based on a very old study (ref 3 in his letter) comparing surfactant with placebo in a different 'era' of neonatology, where respiratory distress syndrome (RDS) was the major cause of death and had a major influence on LOS. Most important is the fact that surfactant therapy compared with placebo has shown decrease in cost both in infants who survived as well as in infants who died. Subsequent studies on resource utilization are clearly different and these have reported LOS in patients who received one of the three animal-derived surfactants.
1,2 Baroutis et al. 3 reported decreased mortality and significantly shorter LOS with poractant alfa (PA), when compared to alveofact or beractant (BE) in a randomized, controlled trial. Fujii et al. 4 reported a nonsignificant decrease in mortality (8 vs 19%) and shorter LOS in a PA-treated group compared with that in the BE-treated group (87 vs 97 days, P ¼ 0.179). In two randomized, controlled trials comparing PA and BE, incidence of patent ductus arteriosus (PDA), as well as the need for medical or surgical ligation of PDA, were significantly less in patients treated with PA, 4,5 which might therefore contribute to shorter LOS. In a study comparing high vs low dose surfactant therapy, LOS was shorter in the high dose group when compared with low dose group (82 vs 99 days). 6 A recently published systematic review and meta-analysis, 7 demonstrated a good correlation between higher surfactant efficacy (mortality reduction) and reduced LOS with poractant alfa (PA). Indeed, in the meta-analysis, PA was associated with both a significant reduced risk of death vs BE (P ¼ 0.02) and a significantly shorter LOS (weighted mean difference: À26.3 [95% CI: À36.5 to À16.07]; P<0.00001). In the most recent randomized trial comparing PA with BE, LOS was not increased in PA group despite a 50% reduction in mortality rate in the PA-treated group (9.8 vs 20%). 8 In light of the evidence cited above, it is incorrect to assume that decreased mortality will automatically lead to longer LOS, especially, when comparing treatment with different surfactants, different timing of administration such as early vs delayed treatment, and different doses such as high vs low dose. It is very likely that higher doses of PA contributed to the positive results seen with PA in all the randomized, controlled trials as well as from meta-analysis published to date. Reasons for shorter LOS accompanying decreased mortality are likely multifactorial. For example, in six of the randomized trials published to date comparing PA with BE, PA treatment was associated with faster weaning of oxygen and pressures, less need for redosing, earlier extubations, less PDA and air-leaks, and improved survival free of bronchopulmonary dysplasia. All of these secondary outcomes might have contributed to the shorter LOS observed in PA treated-infants.
Furthermore, we did not omit LOS results to create an illusory 'mortality advantage' as stated by Dr Egan in his letter. Other retrospective studies comparing mortality differences between animal-derived surfactants do not include LOS amongst covariates in the mortality analysis and therefore our manuscript is entirely consistent with previous and also subsequent study designs in the field of retrospective mortality analyses. 9, 10 In fact, Trembath et al., 10 in a recent report involving 59 342 infants treated with surfactants concluded that, 'Poractant alfa and calfactant were associated with lower incidence of morbidity and mortality as compared to beractant in premature infants. Given that further randomized controlled trials comparing surfactants is unlikely, our findings suggest that the differences in efficacy might be important for clinical practice'. Treatment with PA was associated with fewer air leaks in the first week vs BE and CA, OR ¼ 0.80 (95% CI; 0.69, 0.94) and 0.69 (0.59, 0.82), respectively, and treatment with PA or CA vs BE was associated with lower incidence of BPD, OR ¼ 0.92 (0.88, 0.95) and 0.89 (0.85, 0.93) and mortality, OR ¼ 0.71 (0.65, 0.77) and 0.92 (0.85, 0.99), respectively, which persisted after adjustment. 10 These study findings are entirely consistent with our study findings and other randomized studies involving PA and BE. Furthermore, we have clearly stated in our previous response letter to Dr Cummings, the reasons for not including LOS results in our manuscript discussing mortality as the primary outcome for this study. We used appropriate statistical methods that are typically used with real-world outcomes studies involving large databases. We conducted this study in an ethical manner without any influence whatsoever from the study sponsor and it was subjected to a rigorous peer review process, similar to any other manuscript.
